Request Demo
Fierce Pharma Asia—AbbVie's TL1A deal; Ex-Takeda staffer's guilty plea; Kyowa Kirin's $530M plant investment
Phase 3AcquisitionLicense out/in
AbbVie's TL1A deal with FutureGen Biopharma, an ex-Takeda staffer's scam scheme and Kyowa Kirin's hefty investment in North Carolina made our news this week.
AbbVieh a licensing dealFutureGen Biopharmatech, AbbVie is the latest Big Pharma to Kyowa Kirin in immunology. A former Takeda employee has pleaded guilty to scamming the Japanese drugmaker through a fake consulting firm. Kyowa Kirin will invest up to $530 million in a biologics plant in North Carolina. And more.
1. AbbVie joins TL1A race via $150M upfront deal AbbViehina's FutureGenTL1ATakedaKyowa Kirin
AbbAbbVie paying $150 million upfront for a preclinical inflamFutureGenwel disease candidate from China’s FutureGen Biopharmaceutical, with $1.56 billion in potential milestones. The drug targets TL1A, the same focus of Roche’s $7 billion acquisition of Telavant and Merck’s $11 billion takeover of Prometheus Biosciences last year. AbbVie believes its asset is different from first-generation antibodies.
AbbViestaffer pleads guilty to scamming Takeda out of $2inflammatory bowel diseaseg firmFutureGen BiopharmaceuticalTL1ARocheTelavantMerckPrometheus BiosciencesAbbVie
A former senior level employee at Takeda has pleaded guilty to charges around how she and a co-conspirator allegedly defrauded the drugmaker into paying $2.3 million for fake consulting work. The scheme began in 2022, when the ex-staffer incorporated the sham consulting practice. The two allegedly used the money to buy a diamond ring, a condo and a Mercedes-Benz and to make a down payment on a wedding venue.
3. Kyowa Kirin to expand manufactuTakedaootprint with $530M biologics plant in North Carolina
KyoKyowa Kirin pouring up to $530 million into building a 171,700-square-foot biologics facility in Sanford, North Carolina, as the Japanese company’s first manufacturing site in North Amerca. The size of the investment was significantly larger than the previously announced $200 million. The site is expected to create more than 100 jobs and is expected to be fully operational by 2027.
Kyowa Kirinres jump after BIOSECURE Act's exclusion from defense spending bill
WuXi AppTec and WuXi Biologics got a temporary reprieve as uncertainty grows around the BIOSECURE Act’s legislative path. The bill was denied consideration in the annual National Defense Authorization Act, which determines the Department of Defense’s budget each year. Rep. Brad Wenstrup, the lead GOP sponsor of the bipartisan bill, told Axios that he would seek other routes to move the bill forward.
WuXi AppTecO supWuXi Biologicsrity bill targeting drug developers? Hear CEO John Crowley’s responseDepartment of DefenseAxios
Meanwhile, the Biotechnology Innovation Organization’s CEO John Crowley said he has expressed to Congress that any potential new targets under the BIOSEUCRE Act must be based on “very clear and convincing evidence.” A recent request for an intelligence briefing on GenScript and its related businesses raised the faintest possibility of a potential expansion of the bill. However, Kevin Noonan, Ph.D., from law firm MBHB argued that the bill wouldn’t target drug developers.
6. Analysts tipBiotechnology Innovation Organizationrival LeqembiGenScript
Eli Lilly tippedLillyeapfrog Eisai, Biogen and take control of $13B Alzheimer's market
As ELillylly’s donanemab sailEisairoBiogen FDA advisory committee meeting, Bloomberg Intelligence analysts figured the drug could beat Eisai and Biogen’s Leqembi on sales in 12 months after a potential approval in part because of its more convenient dosing and the ability to stop treatment. Nevertheless, William Blair analysts viewed donanemab’s potential approval as an opportunity to boost the overall Alzheimer’s disease market for anti-amyloid drugs.
AluAlumis looking for an IPO to acceleratTYK2 inhibitorTYK2e development of its immunopsoriasisline. The company’s lead asset, a TYK2 inhibitor coded ESK-001, was in-licensed from China’s Haisco Pharma back in 2021 for up to $180 million in upfront and potential milestone payments. The California biotech now aims to advance the drug—a potential competitor to Bristol Myers Squibb’s Sotyktu—into phase 3 trials in plaque psoriasis later this year.
8. European antitrust watchdog accuses API manufacturer Alchem of engaging in price-fixing scheme
9. FDA accepts Eisai's monthly dosing application for LeAlchem sets Jan. 25 decision date
11. Lotus Pharmarus' PD-1 Tevabitor Loqtorzi scores in phase 3 liver cancer trial
12. Junshi extends PaPD-1rs in HealtLoqtorzi to improve access liver cancerassachusetts
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.